Cardiovascular profile improvement during Natalizumab treatment.

about

Cardiovascular profile improvement during Natalizumab treatment.

Item

http://www.wikidata.org/entity/Q47907093

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Cardiovascular profile improvement during Natalizumab treatment.

@en

Cardiovascular profile improvement during Natalizumab treatment.

@nl

type

Item

label

Cardiovascular profile improvement during Natalizumab treatment.

@en

Cardiovascular profile improvement during Natalizumab treatment.

@nl

prefLabel

Cardiovascular profile improvement during Natalizumab treatment.

@en

Cardiovascular profile improvement during Natalizumab treatment.

@nl

P1476

Cardiovascular profile improvement during Natalizumab treatment.

@en

P2093

Anna De Rosa

http://www.w3.org/2001/XMLSchema#string

Cinzia Valeria Russo

http://www.w3.org/2001/XMLSchema#string

Francesco Saccà

http://www.w3.org/2001/XMLSchema#string

Roberta Lanzillo

http://www.w3.org/2001/XMLSchema#string

Roberto Albero

http://www.w3.org/2001/XMLSchema#string

Vincenzo Brescia Morra

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial

Cholesterol and markers of cholesterol turnover in multiple sclerosis: relationship with disease outcomes.

Uric acid in relapsing-remitting multiple sclerosis: a 2-year longitudinal study.

A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis

Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment.

Relapsing-remitting multiple sclerosis patients display an altered lipoprotein profile with dysfunctional HDL.

An adverse lipid profile is associated with disability and progression in disability, in people with MS.

A review of the ethics of the use of placebo in clinical trials for relapsing-remitting multiple sclerosis therapeutics.

Modulation of adhesion molecules by cholesterol-lowering therapy in mononuclear cells from hypercholesterolemic patients.

P2888

s11011-017-0169-z

P304

981-986

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11011-017-0169-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Raffaele Palladino

Marcello Moccia

A Carotenuto

P577

2017-12-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29256149

http://www.w3.org/2001/XMLSchema#string